Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells

@inproceedings{MartinSanchez2017DeferasiroxinducedID,
  title={Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells},
  author={Diego Martin-Sanchez and Angel Gallegos-Villalobos and Miguel Fontecha-Barriuso and Susana Carrasco and Maria Dolores Sanchez-Ni{\~n}o and Francisco J. L{\'o}pez-Hern{\'a}ndez and Marta Ruiz-Ortega and Jes{\'u}s Egido and Alberto Ortiz and Ana Bel{\'e}n Sanz},
  booktitle={Scientific reports},
  year={2017}
}
Iron deficiency has been associated with kidney injury. Deferasirox is an oral iron chelator used to treat blood transfusion-related iron overload. Nephrotoxicity is the most serious and common adverse effect of deferasirox and may present as an acute or chronic kidney disease. However, scarce data are available on the molecular mechanisms of nephrotoxicity. We explored the therapeutic modulation of deferasirox-induced proximal tubular cell death in culture. Deferasirox induced dose-dependent… CONTINUE READING
1 Extracted Citations
0 Extracted References
Similar Papers

Similar Papers

Loading similar papers…